SEATTLE--(BUSINESS WIRE)--Acucela Inc. (TOKYO:4589), a clinical-stage biotechnology company that specializes in discovering and developing novel drug candidates to potentially treat and slow the progression of sight-threatening ophthalmic diseases, today announced that it has made significant progress on the three strategic imperatives previously announced in its 2014 Annual Report to Shareholders to increase the value of the Company and enhance shareholder return: maximizing the value of emixustat, advancing research, and pursuing business development opportunities to grow the Company’s pipeline. The progress on each of these three imperatives is detailed below.
Help employers find you! Check out all the jobs and post your resume.
